The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.
High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User.The growth of this market is attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.Ask for FREE PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391Driver: Need for cost containment in pharmaceutical RAccording to the California Biomedical Research Association (CBRA), it takes an average of 12 years for a drug to travel from the research lab to the patient, including 1–6 years for toxicology studies alone.
In addition, only five in 5,000, or 10%, of the drugs that begin preclinical testing ever make it to human testing.
The Tufts Center for the Study of Drug Development (U.S.) report published in the Journal of Health Economics in March 2016 estimates that the average cost to develop and gain a marketing approval for a new drug amounted to USD 2.56 billion.The high cost and long duration of drug development are compelling pharmaceutical companies to revise their R expenditure.
A confocal microscope can cost more than USD 200,000.